Feline Osteoarthritis Management

Deabold, Kelly A.; Montalbano, Christina; Miscioscia, Erin

doi:10.1016/j.cvsm.2023.02.015

Cited by 2 publications

(1 citation statement)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken together, these tools allow the assessment of the feline OA pain in its globality leading to personalized treatment, preventive or curative, targeting or not the sensitization. Currently, multimodal, integrative management of the feline OA pain [ 39 ] presents more characteristics of “one size fits all” than a personalized plan, including analgesic medications [ 40 ], biologics (regenerative) medicine, dietary modifications [ 41 , 42 , 43 ], nutraceutical supplementation [ 43 ], environmental adaptations, and complementary and alternative medicine such as physical rehabilitation or acupuncture [ 44 ], without real evidence of benefits or deleterious effects.…”

Section: Discussionmentioning

confidence: 99%

Concurrent Validation of MI-CAT(V), a Clinical Metrology Instrument for Veterinarians Assessing Osteoarthritis Pain in Cats, through Testing for Firocoxib Analgesic Efficacy in a Prospective, Randomized, Controlled, and Blinded Study

Delsart,

Otis,

Leung

et al. 2024

Animals

View full text Add to dashboard Cite

Veterinarians face the lack of a rapid, reliable, inexpensive, and treatment-sensitive metrological instrument reflecting feline osteoarthritis (OA) pain. The Montreal Instrument for Cat Arthritis Testing, for Use by Veterinarians (MI-CAT(V)) has been refined in 4 sub-sections, and we proposed its concurrent validation. Cats naturally affected by OA (n = 32) were randomly distributed into 4 groups of firocoxib analgesic (Gr. A: 0.40; B: 0.25; C: 0.15, and P: 0.00 mg/kg bodyweight). They were assessed during Baseline, Treatment, and Recovery periods using MI-CAT(V) and objective outcomes (effort path, stairs assay compliance, and actimetry). The MI-CAT(V) total score correlated to the effort path and actimetry (RhoS = −0.501 to −0.453; p < 0.001), also being sensitive to treatment responsiveness. The pooled treatment group improved its total, gait, and body posture scores during Treatment compared to the Baseline, Recovery, and placebo group (p < 0.05). The MI-CAT(V) suggested a dose-(especially for Gr. B) and cluster-response. Cats in the moderate and severe MI-CAT(V) clusters responded to firocoxib with a remaining analgesic effect, while the mild cluster seemed less responsive and experienced a negative rebound effect. The MI-CAT(V) was validated for its OA pain severity discriminatory abilities and sensitivity to firocoxib treatment, providing a new perspective for individualized care.

show abstract